

Epitope Mapping of Monoclonal Antibody PMAb-38 Against Dog Podoplanin

Yao-Wen Chang,¹ Shinji Yamada,¹ Mika K. Kaneko,¹ and Yukinari Kato^{1,2}

Podoplanin (PDPN), a type I transmembrane sialoglycoprotein, is extensively expressed by normal lymphatic endothelial cells, renal podocytes, and pulmonary type I alveolar cells. Nevertheless, increased expression of PDPN in malignant tumors not only associates with poor prognosis but also facilitates hematogenous metastasis through interaction with C-type lectin-like receptor-2 presented on platelets, followed by PDPN-mediated platelet activation. We previously reported a novel PMAb-38 antibody, an anti-dog PDPN (dPDPN) monoclonal antibody, which specifically recognizes PDPN in squamous cell carcinomas melanomas and cancer-associated fibroblasts in canine cancer tissues. However, the specific binding with the epitope of PMAb-38 remains undefined. In this study, flow cytometry was utilized to investigate the epitope of PMAb-38, which was determined using a series of deletion or point mutants of dPDPN. The results revealed that the critical epitope of PMAb-38 is Tyr67 and Glu68 of dPDPN.

Keywords: podoplanin, epitope, dog PDPN

Introduction

PODOPLANIN (PDPN), a type I transmembrane sialoglycoprotein, is also known as Aggrus/T1 α -2/gp36.⁽¹⁻³⁾ The first characterized dog PDPN (dPDPN) is reported to be gp40.⁽⁴⁾ Notably, PDPN is expressed in normal kidney podocytes, pulmonary type I alveolar cells, lymphatic endothelial cells (LECs), chondrocytes, myofibroblasts, and mesothelial cells.⁽⁵⁻¹⁰⁾ However, higher expression of PDPN has also been observed in different tumor types, including squamous cell carcinoma (SCC),⁽¹¹⁾ melanoma,⁽¹²⁾ central nervous system tumors,⁽¹³⁾ glioblastoma,^(14,15) mesothelioma,⁽⁷⁾ and breast cancers.^(16,17) Recent clinical studies have provided evidence of association of increased PDPN expression with poor prognosis and cancer metastasis.^(10,18,19) Furthermore, PDPN elicits tumor cell-induced platelet aggregation response through the activation of platelet C-type lectin-like receptor 2 to facilitate cancer progression and metastasis.⁽²⁰⁻²³⁾ These evidences indicate that the establishment and production of anti-PDPN monoclonal antibodies (mAbs) is imperative to develop novel therapeutic strategy against cancer development and progression to metastasis.

Recently, we developed a novel PMAb-38 mAb, which specifically recognizes dPDPN in renal podocytes, in contrast to LECs or type I alveolar cells, by immunohistochemical analysis.⁽²⁴⁾ Moreover, PMAb-38 also recognizes dPDPN of SCCs, melanomas, and cancer-associated fibroblasts (CAFs)

in cancer tissues.^(12,25) Therefore, this study was initiated to investigate the epitope of PMAb-38 using deletion or point mutants of dPDPN in Chinese hamster ovary (CHO)-K1 cells by flow cytometry.

Materials and Methods

Cell lines

CHO-K1 was procured from the American Type Culture Collection (ATCC, Manassas, VA). CHO-K1 cells were transfected with the dPDPN-MAP tag plasmid using Lipofectamine LTX (Thermo Fisher Scientific, Inc., Waltham, MA) according to manufacturer's protocol. CHO-K1 and transfectants were cultured in RPMI 1640 medium (Nacalai Tesque, Inc., Kyoto, Japan) and supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific, Inc.), 100 U/mL of penicillin, 100 μ g/mL of streptomycin, and 25 μ g/mL of amphotericin B (Nacalai Tesque, Inc.) at 37°C in a humidified atmosphere of 5% CO₂ and 95% air. Zeocin (0.5 mg/mL; InvivoGen, San Diego, CA) was added for producing and culturing each transfectant.

Production of dPDPN mutants

The amplified dPDPN complementary DNA was subcloned into a pCAG vector (Wako Pure Chemical Industries, Ltd.) and a MAP tag was added at the N-terminus. Deletion

¹Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

²New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan.

mutants of dPDPN were generated using a HotStar HiFidelity PCR (Qiagen, Inc., Hilden, Germany) with oligonucleotides containing the desired mutations. PCR amplicons bearing the desired mutations were subcloned into pCAG vector using an In-Fusion PCR cloning kit (Clontech, Palo Alto, CA). Substitutions of amino acids (aa) to alanine in the dPDPN sequence were achieved using a QuikChange lightning site-directed mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA).

Flow cytometry

Cells were harvested after brief exposure to 0.25% trypsin/1 mM ethylenediaminetetraacetic acid (Nacalai Tesque, Inc.). After washing with 0.1% bovine serum albumin in phosphate-buffered saline, the cells were treated with 10 μ g/mL of PMAb-38 and 5 μ g/mL of anti-MAP tag (clone: PMAb-1) for 35 minutes at 4°C followed by treatment with Alexa

Fluor 488-conjugated anti-mouse IgG (1:1000; Cell Signaling Technology, Inc., Danvers, MA) and Oregon Green-conjugated anti-rat IgG (1:1000; Thermo Fisher Scientific, Inc.), respectively. Fluorescence data were acquired using Cell Analyzer EC800 (Sony, Corp., Tokyo, Japan).

Results and Discussion

Previously, we developed a novel PMAb-38 mAb, which exhibited high specificity and sensitivity toward dPDPN and is highly suitable for the detection of renal glomerulus podocytes in immunohistochemical analysis.⁽²⁴⁾ Interestingly, PMAb-38 can be used to detect dPDPN expressed by oral and skin SCCs.⁽²⁵⁾ CAFs and canine melanoma cells were also recognized by PMAb-38.^(12,25) Taken together, these findings suggest that the epitope mapping of PMAb-38 could provide a promising target for the PDPN-based diagnosis and cancer therapy.




FIG. 1. Epitope mapping of PMAb-38 using deletion mutants of dPDPN. **(A)** Illustration of nine dPDPN deletion mutants: dN23, dN30, dN50, dN60, dN65, dN70, dN75, dN80, and dN110. **(B)** Epitope mapping of deletion mutants of dPDPN by flow cytometric analysis. Deletion mutants were incubated with anti-MAP tag PMAb-1 (left panel, red), PMAb-38 (right panel, blue), or buffer control (black) for 35 minutes at 4°C, followed by addition of corresponding secondary antibodies, respectively. dPDPN, dog podoplanin.

For this study, nine deletion mutants of dPDPN were generated (Fig. 1A). Stable transfections of dPDPN-mutant clones were established in CHO-K1 cells, including dN23 (corresponding to 23–169 aa), dN30 (corresponding to 30–169 aa), dN50 (corresponding to 50–169 aa), dN60 (corre-

sponding to 60–169 aa), dN65 (corresponding to 65–169 aa), dN70 (corresponding to 70–169 aa), dN75 (corresponding to 75–169 aa), dN80 (corresponding to 80–169 aa), and dN110 (corresponding to 110–169 aa). All dPDPN deletion mutants were tagged with N-terminal MAP and therefore were




FIG. 2. Epitope mapping of PMAb-38 using point mutants of dPDPN. (A, B) Flow cytometry. Stable point mutants expressing D60A, G61A, A62G, T63A, E64A, E65A, P66A, Y67A, E68A, S69A, and G70A of dPDPN were treated with PMAb-1 (A) or PMAb-38 (B) for 35 minutes at 4°C, followed by addition of corresponding secondary antibodies, respectively. (C) Schematic illustration of the epitope recognized by PMAb-38.

analyzed using flow cytometry for epitope mapping of PMab-38. Flow cytometric analysis revealed that PMab-1 (anti-MAP tag mAb) detected all the dPDPN deletion mutants, including dN23, dN30, dN50, dN60, dN65, dN70, dN75, dN80, and dN110 (Fig. 1B, left). However, a significant loss in the reaction of PMab-38 was observed with dN70, dN75, dN80, and dN110 (Fig. 1B, right). These results indicate that N-terminus of PMab-38 epitope is located between 65th and 70th aa.

Next, to further investigate the crucial epitope of PMab-38, we produced a series of point mutants of dPDPN in CHO-K1 cells, including D60A, G61A, A62G, T63A, E64A, E65A, P66A, Y67A, E68A, S69A, and G70A. All deletion mutants were recognized by PMab-1 (Fig. 2A). Notably, PMab-38 reacted with all these mutants, except with Y67A and E68A (Fig. 2B). These results provide strong direct evidence that Tyr67 and Glu68 are the crucial epitopes of PMab-38 (Fig. 2C). This YE motif of dPDPN is not conserved among the other species.

Although detection of PMab-38 for renal glomerulus, SCCs, melanoma, and CAFs using immunohistochemistry and flow cytometry was successful,^(12,24,25) our results revealed that PMab-38 has limitation for dPDPN recognition by Western blot analysis (data not shown). One reason might be that PMab-38 has high affinity binding to undenatured dPDPN.

Taken together, these results demonstrated that PMab-38 is a potential diagnostic target for the detection of dPDPN using flow cytometry. Furthermore, the study also revealed Tyr67 and Glu68 as the crucial epitopes of dPDPN for specific binding with PMab-38. This study also provides evidence on the potential application of PMab-38 in unveiling pathophysiological function of dPDPN.

Acknowledgments

This work was supported, in part, by the Basic Science and Platform Technology Program for Innovative Biological Medicine from Japan Agency for Medical Research and development, AMED (Y.K.), by Project for utilizing glycans in the development of innovative drug discovery technologies from AMED (Y.K.), and by Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research [BINDS]) from AMED.

Author Disclosure Statement

Y.K. received research funding from Ono Pharmaceutical Co., Ltd.

References

1. Kaneko MK, Kato Y, Kitano T, and Osawa M: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. *Gene* 2006;378:52–57.
2. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, and Tsuruo T: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. *J Biol Chem* 2003;278:51599–51605.
3. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, and Quintanilla M: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. *Int J Cancer* 2005;113:899–910.

4. Zimmer G, Klenk HD, and Herrler G: Identification of a 40-kDa cell surface sialoglycoprotein with the characteristics of a major influenza C virus receptor in a Madin-Darby canine kidney cell line. *J Biol Chem* 1995;270:17815–17822.
5. Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, Pammer J, Sturzl M, Kerjaschki D, Alitalo K, and Tschachler E: Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. *Lab Invest* 1999;79:243–251.
6. Matsui K, Breiteneder-Geleff S, Soleiman A, Kowalski H, and Kerjaschki D: Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. *Nephrol Dial Transplant* 1999;14(Suppl 1):9–11.
7. Kimura N, and Kimura I: Podoplanin as a marker for mesothelioma. *Pathol Int* 2005;55:83–86.
8. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, and Kerjaschki D: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. *Am J Pathol* 1997;151:1141–1152.
9. Ugorski M, Dziegiel P, and Suchanski J: Podoplanin—A small glycoprotein with many faces. *Am J Cancer Res* 2016;6:370–386.
10. Astarita JL, Acton SE, and Turley SJ: Podoplanin: Emerging functions in development, the immune system, and cancer. *Front Immunol* 2012;3:283.
11. Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Lee JJ, Retzbach EP, Shen Y, Fatahzadeh M, Baredes S, Kalyoussef E, Honma M, Adelson ME, Kaneko MK, Kato Y, Young MA, Deluca-Rapone L, Shienbaum AJ, Yin K, Jensen LD, and Goldberg GS: Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. *Oncotarget* 2015;6:9045–9060.
12. Ogasawara S, Honma R, Kaneko MK, Fujii Y, Kagawa Y, Konnai S, and Kato Y: Podoplanin expression in canine melanoma. *Monoclon Antib Immunodiagn Immunother* 2016;35:304–306.
13. Mishima K, Kato Y, Kaneko MK, Nakazawa Y, Kunita A, Fujita N, Tsuruo T, Nishikawa R, Hirose T, and Matsutani M: Podoplanin expression in primary central nervous system germ cell tumors: A useful histological marker for the diagnosis of germinoma. *Acta Neuropathol* 2006;111:563–568.
14. Grau SJ, Trillsch F, Tonn JC, Goldbrunner RH, Noessner E, Nelson PJ, and von Luettichau I: Podoplanin increases migration and angiogenesis in malignant Glioma. *Int J Clin Exp Pathol* 2015;8:8663–8670.
15. Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, and Zalutsky MR: Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. *Nucl Med Biol* 2010;37:785–794.
16. Wahal SP, Goel MM, and Mehrotra R: Lymphatic vessel assessment by podoplanin (D2-40) immunohistochemistry in breast cancer. *J Cancer Res Ther* 2015;11:798–804.
17. Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsky P, Jesch B, Heinzl H, and Birner P: Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. *Breast Cancer Res Treat* 2012;134:237–244.
18. Xu Y, Ogose A, Kawashima H, Hotta T, Ariizumi T, Li G, Umezumi H, and Endo N: High-level expression of podoplanin

- in benign and malignant soft tissue tumors: Immunohistochemical and quantitative real-time RT-PCR analysis. *Oncol Rep* 2011;25:599–607.
19. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, and Mao L: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. *Cancer* 2006;107:563–569.
 20. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y, and Narimatsu H: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. *Cancer Sci* 2008;99:54–61.
 21. Chang YW, Hsieh PW, Chang YT, Lu MH, Huang TF, Chong KY, Liao HR, Cheng JC, and Tseng CP: Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. *Oncotarget* 2015;6:42733–42748.
 22. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T, and Fujita N: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. *Am J Pathol* 2007;170:1337–1347.
 23. Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, and Kato Y: Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. *Cancer Sci* 2012;103:1913–1919.
 24. Honma R, Kaneko MK, Ogasawara S, Fujii Y, Konnai S, Takagi M, and Kato Y: Specific detection of dog podoplanin expressed in renal glomerulus by a novel monoclonal antibody PMab-38 in immunohistochemistry. *Monoclon Antib Immunodiagn Immunother* 2016;35:212–216.
 25. Kaneko MK, Honma R, Ogasawara S, Fujii Y, Nakamura T, Saidoh N, Takagi M, Kagawa Y, Konnai S, and Kato Y: PMab-38 recognizes canine podoplanin of squamous cell carcinomas. *Monoclon Antib Immunodiagn Immunother* 2016;35:263–266.

Address correspondence to:

*Yukinari Kato
New Industry Creation Hatchery Center
Tohoku University
Department of Antibody Drug Development
Tohoku University Graduate School of Medicine
2-1 Seiryomachi
Aoba-ku
Sendai
Miyagi 980-8575
Japan*

*E-mail: yukinari-k@bea.hi-ho.ne.jp,
yukinarikato@med.tohoku.ac.jp*

Received: September 8, 2017

Accepted: October 19, 2017